NasdaqGS:OLMABiotechs
A Look At Olema Pharmaceuticals (OLMA) Valuation After New Preclinical Breast Cancer Data
Olema Pharmaceuticals (OLMA) shares are back in focus after the company released new preclinical data for palazestrant and KAT6 inhibitor OP-3136 at the AACR Annual Meeting, highlighting their combined activity in ER+/HER2- breast cancer models.
See our latest analysis for Olema Pharmaceuticals.
The latest AACR data arrive after a volatile year, with a 19.46% 1 month share price return and a 33.47% year to date share price decline, alongside a very large 1 year total shareholder return that...